Drug Profile
Research programme: anti-infective therapeutics - ChemDiv/Janssen
Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator ChemDiv; Janssen
- Class Anti-infectives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Infections
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for research development in Infections in USA
- 23 Jan 2018 ChemDiv announces the expansion of its hit identification collaboration with Janssen to find anti-infective drug candidates
- 23 Jan 2018 Early research in Infections in USA (unspecified route)